Review
BibTex RIS Cite

Hematopoetik kök hücrelerin klinik kullanımı

Year 2016, Volume: 1 Issue: 1, 10 - 18, 01.02.2016

Mutlu Arat

Abstract

Hematopoetik kök hücreler (HKH) klinik olarak 1950’lerden beri kullanılmaktadır. Kemik iliğinin benign rahatsızlıklarında (Örn. Edinsel ağır aplastik anemi, Fankoni anemisi, Talasemi majör, Orak hücreli anemi gibi) terapötik ve malign rahatsızlıklarında postremisyon tedavi konsolidasyonu amaçlı kullanıma rutin olarak girmesi yetmişli yıllara doğru olmuştur. Yılda artık 10-80 bin HKH nakli yapılmakta olup, bir milyonuncu nakil yakın zamanda yapılmıştır. Ülkemizde yapılan işlemlerde son beş yıl içerisinde nakil merkezi sayısı ikiye katlanmış ve toplam nakil sayısı 3.000’lere ulaşmıştır. Bu evrensel ve standart tedavi yönteminin başarısı, onarım tıbbı amaçlı çalışmaların da hızlanmasına yol açmıştır. Kardiyoloji bu alanda başı çekmiş, takiben nörolojik bilimler ve karaciğer rahatsızlıklarında kemik iliği veya çevre kanı tabanlı HKH’lerin çeşitli rahatsızlıklarda deneysel amaçlı klinik kullanımının arttığı gözlenmiştir. Ülkemizde de bu konuda az sayıda klinik araştırma yapılmıştır. Bu konuda erişkin kök hücrelerin, mezenkimal kök hücreler (MKH) dışında standart kinik kullanımına ait bir gelişme yaşanmazken, MKH ve diğer erişkin ve embriyonik kök hücrelerin onarım tıbbındaki araştırmaları olanca hızıyla devam etmektedir. Ülkemizde HKH nakli yayınlanmış standart evrensel endikasyonlarda uygulanmakta ve geri ödenmekteyken, hematoloji dışı erişkin HKH’lerin kullanımı T.C. Sağlık Bakanlığı’nın yasal iznine tabidir. Diğer yandan embriyonik kök hücrelerin klinik kullanımı tamamen yasaklanmıştır. Bu derlemede standart klinik kullanım, endikasyonları, tipleri, sık komplikasyonları ile ülkemizde yürütülmüş olan HKH tabanlı onarım tıbbı yaklaşımları gözden geçirilmiştir.

Keywords

Hematopoetik kök hücreler klinik kullanım mezenkimal kök hücreler

References

  • Thomas ED. A history of allogeneic hematopoietic cell transplantation. In: Appelbaum FR, Forman SJ, Negrin RS, Blume KG, editors. Thomas’ Hematopoietic Cell Transplantation. 4th ed. Massachusetts: Wiley-Blackwell; 2008. p. 3-7.
  • Armitage JO. The history of autologous hematopoietic cell transplantation. In: Appelbaum FR, Forman SJ, Negrin RS, Blume KG, editors. Thomas’ Hematopoietic Cell Transplantation. 4th ed.Massachusetts: Wiley-Blackwell; 2008. p. 8-14.
  • Blood and Marrow Transplantation Subcommittee, Turkish Societ of Hematology. Blood and marrow transplantation activities among adult patients in Turkey. Cytotherapy 2000;2:377-9.
  • Arat M, Arpaci F, Ertem M, Gürman G. Turkish Transplant Registry: a comparative analysis of national activity with the EBMT European Activity Survey. Bone Marrow Transplant 2008;42:142-5.
  • Ljungman P, Gratwohl A. Indications and current practice for allogeneic and autologous HSCT for hematological disorders, solid tumors and immune disorders. In: Apperley J, Carreras E, Gluckman E, Gratwohl A, Masszi T, editors. The EBMT Handbook. Hematopoietic Stem Cell Transplantation. 5th ed. 2008. p. 319-26.
  • Larghero J, Garcia J, Gluckman E. Sources and procurement of stem cells. In: Apperley J, Carreras E, Gluckman E, Gratwohl A, Masszi T, editors. The EBMT Handbook. Hematopoietic Stem Cell Transplantation. 5th ed. 2008. p. 113-27.
  • Carreras E. HKHT sonrası erken komplikasyonlar. EBMT El Kitabı. 6. Baskı. Hematopoetik Kök Hücre Transplantasyonu; 2012. s. 209-31.
  • Devergie A. Graft versus Host Disease. In: Apperley J, Carreras E, Gluckman E, Gratwohl A, Masszi T, editors. The EBMT Handbook. Hematopoietic Stem Cell Transplantation. 5th ed. 2008. p. 219-33.
  • Tichelli A, Rovó A, Passweg J, Schwarze CP, Van Lint MT, Arat M, et al. Late complications after hematopoietic stem cell transplantation. Expert Rev Hematol 2009;2:583-601.
  • Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Bone Marrow Transplant 2012;47:337-41.
  • Gratwohl A, Passweg J, Baldomero H, Horisberger B, Urbano-Ispizua A. Economics, health care systems and utilization of haematopoietic stem cell transplants in Europe. Br J Haematol 2002;117:451-68.
  • Gratwohl A, Baldomero H, Frauendorfer K, Niederwieser D. Why are there regional differences in stem cell transplantation activity? An EBMT analysis. Bone Marrow Transplant 2008;42:7-10.
  • Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, et al. Hematopoietic stem cell transplantation: a global perspective. JAMA 2010;303:1617-24.
  • Passweg JR, Baldomero H, Peters C, Gaspar HB, Cesaro S, Dreger P, et al. Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation. Bone Marrow Transplant 2014;49:744-50.
  • Ozbaran M, Omay SB, Nalbantgil S, Kultursay H, Kumanlioglu K, Nart D, et al. Autologous peripheral stem cell transplantation in patients with congestive heart failure due to ischemic heart disease. Eur J Cardiothorac Surg 2004;25:342-50.
  • Durdu S, Akar AR, Arat M, Sancak T, Eren NT, Ozyurda U. Autologous bone-marrow mononuclear cell implantation for patients with Rutherford grade II-III thromboangiitis obliterans. J Vasc Surg 2006;44:732-9.
  • Akar AR, Durdu S, Arat M, Kilickap M, Kucuk NO, Arslan O, et al. Five-year follow-up after transepicardial implantation of autologous bone marrow mononuclear cells to ungraftable coronary territories for patients with ischaemic cardiomyopathy. Eur J Cardiothorac Surg 2009;36:633-43.
  • Deda H, Inci MC, Kürekçi AE, Sav A, Kayihan K, Ozgün E, et al. Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow-derived hematopoietic stem cell transplantation: a 1-year follow-up. Cytotherapy 2009;11:18-25.
  • Ozdemir M, Attar A, Kuzu I, Ayten M, Ozgencil E, Bozkurt M, et al. Stem cell therapy in spinal cord injury: in vivo and postmortem tracking of bone marrow mononuclear or mesenchymal stem cells. Stem Cell Rev 2012;8:953-62.
  • Adas G, Kemik O, Eryasar B, Okcu A, Adas M, Arikan S, et al. Treatment of ischemic colonic anastomoses with systemic transplanted bone marrow derived mesenchymal stem cells. Eur Rev Med Pharmacol Sci 2013;17:2275-85.
  • Flynn JM, Matthews KR. Stem cell research in the Greater Middle East: the importance of establishing policy and ethics interoperability to foster international collaborations. Stem Cell Rev 2010;6:143-50.
  • Arda B, Aciduman A. An evaluation regarding the current situation of stem cell studies in Turkey. Stem Cell Rev 2009;5:130-4.

Year 2016, Volume: 1 Issue: 1, 10 - 18, 01.02.2016

Mutlu Arat

Abstract

References

  • Thomas ED. A history of allogeneic hematopoietic cell transplantation. In: Appelbaum FR, Forman SJ, Negrin RS, Blume KG, editors. Thomas’ Hematopoietic Cell Transplantation. 4th ed. Massachusetts: Wiley-Blackwell; 2008. p. 3-7.
  • Armitage JO. The history of autologous hematopoietic cell transplantation. In: Appelbaum FR, Forman SJ, Negrin RS, Blume KG, editors. Thomas’ Hematopoietic Cell Transplantation. 4th ed.Massachusetts: Wiley-Blackwell; 2008. p. 8-14.
  • Blood and Marrow Transplantation Subcommittee, Turkish Societ of Hematology. Blood and marrow transplantation activities among adult patients in Turkey. Cytotherapy 2000;2:377-9.
  • Arat M, Arpaci F, Ertem M, Gürman G. Turkish Transplant Registry: a comparative analysis of national activity with the EBMT European Activity Survey. Bone Marrow Transplant 2008;42:142-5.
  • Ljungman P, Gratwohl A. Indications and current practice for allogeneic and autologous HSCT for hematological disorders, solid tumors and immune disorders. In: Apperley J, Carreras E, Gluckman E, Gratwohl A, Masszi T, editors. The EBMT Handbook. Hematopoietic Stem Cell Transplantation. 5th ed. 2008. p. 319-26.
  • Larghero J, Garcia J, Gluckman E. Sources and procurement of stem cells. In: Apperley J, Carreras E, Gluckman E, Gratwohl A, Masszi T, editors. The EBMT Handbook. Hematopoietic Stem Cell Transplantation. 5th ed. 2008. p. 113-27.
  • Carreras E. HKHT sonrası erken komplikasyonlar. EBMT El Kitabı. 6. Baskı. Hematopoetik Kök Hücre Transplantasyonu; 2012. s. 209-31.
  • Devergie A. Graft versus Host Disease. In: Apperley J, Carreras E, Gluckman E, Gratwohl A, Masszi T, editors. The EBMT Handbook. Hematopoietic Stem Cell Transplantation. 5th ed. 2008. p. 219-33.
  • Tichelli A, Rovó A, Passweg J, Schwarze CP, Van Lint MT, Arat M, et al. Late complications after hematopoietic stem cell transplantation. Expert Rev Hematol 2009;2:583-601.
  • Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Bone Marrow Transplant 2012;47:337-41.
  • Gratwohl A, Passweg J, Baldomero H, Horisberger B, Urbano-Ispizua A. Economics, health care systems and utilization of haematopoietic stem cell transplants in Europe. Br J Haematol 2002;117:451-68.
  • Gratwohl A, Baldomero H, Frauendorfer K, Niederwieser D. Why are there regional differences in stem cell transplantation activity? An EBMT analysis. Bone Marrow Transplant 2008;42:7-10.
  • Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, et al. Hematopoietic stem cell transplantation: a global perspective. JAMA 2010;303:1617-24.
  • Passweg JR, Baldomero H, Peters C, Gaspar HB, Cesaro S, Dreger P, et al. Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation. Bone Marrow Transplant 2014;49:744-50.
  • Ozbaran M, Omay SB, Nalbantgil S, Kultursay H, Kumanlioglu K, Nart D, et al. Autologous peripheral stem cell transplantation in patients with congestive heart failure due to ischemic heart disease. Eur J Cardiothorac Surg 2004;25:342-50.
  • Durdu S, Akar AR, Arat M, Sancak T, Eren NT, Ozyurda U. Autologous bone-marrow mononuclear cell implantation for patients with Rutherford grade II-III thromboangiitis obliterans. J Vasc Surg 2006;44:732-9.
  • Akar AR, Durdu S, Arat M, Kilickap M, Kucuk NO, Arslan O, et al. Five-year follow-up after transepicardial implantation of autologous bone marrow mononuclear cells to ungraftable coronary territories for patients with ischaemic cardiomyopathy. Eur J Cardiothorac Surg 2009;36:633-43.
  • Deda H, Inci MC, Kürekçi AE, Sav A, Kayihan K, Ozgün E, et al. Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow-derived hematopoietic stem cell transplantation: a 1-year follow-up. Cytotherapy 2009;11:18-25.
  • Ozdemir M, Attar A, Kuzu I, Ayten M, Ozgencil E, Bozkurt M, et al. Stem cell therapy in spinal cord injury: in vivo and postmortem tracking of bone marrow mononuclear or mesenchymal stem cells. Stem Cell Rev 2012;8:953-62.
  • Adas G, Kemik O, Eryasar B, Okcu A, Adas M, Arikan S, et al. Treatment of ischemic colonic anastomoses with systemic transplanted bone marrow derived mesenchymal stem cells. Eur Rev Med Pharmacol Sci 2013;17:2275-85.
  • Flynn JM, Matthews KR. Stem cell research in the Greater Middle East: the importance of establishing policy and ethics interoperability to foster international collaborations. Stem Cell Rev 2010;6:143-50.
  • Arda B, Aciduman A. An evaluation regarding the current situation of stem cell studies in Turkey. Stem Cell Rev 2009;5:130-4.
There are 22 citations in total.

Details

Journal Section Articles
Authors

Mutlu Arat

Publication Date February 1, 2016
Published in Issue Year 2016 Volume: 1 Issue: 1

Cite

APA Arat, M. (2016). Hematopoetik kök hücrelerin klinik kullanımı. İstanbul Bilim Üniversitesi Florence Nightingale Transplantasyon Dergisi, 1(1), 10-18. https://doi.org/10.5606/fng.transplantasyon.2016.003
AMA Arat M. Hematopoetik kök hücrelerin klinik kullanımı. İstanbul Bilim Üniversitesi Florence Nightingale Transplantasyon Dergisi. February 2016;1(1):10-18. doi:10.5606/fng.transplantasyon.2016.003
Chicago Arat, Mutlu. “Hematopoetik kök hücrelerin Klinik kullanımı”. İstanbul Bilim Üniversitesi Florence Nightingale Transplantasyon Dergisi 1, no. 1 (February 2016): 10-18. https://doi.org/10.5606/fng.transplantasyon.2016.003.
EndNote Arat M (February 1, 2016) Hematopoetik kök hücrelerin klinik kullanımı. İstanbul Bilim Üniversitesi Florence Nightingale Transplantasyon Dergisi 1 1 10–18.
IEEE M. Arat, “Hematopoetik kök hücrelerin klinik kullanımı”, İstanbul Bilim Üniversitesi Florence Nightingale Transplantasyon Dergisi, vol. 1, no. 1, pp. 10–18, 2016, doi: 10.5606/fng.transplantasyon.2016.003.
ISNAD Arat, Mutlu. “Hematopoetik kök hücrelerin Klinik kullanımı”. İstanbul Bilim Üniversitesi Florence Nightingale Transplantasyon Dergisi 1/1 (February 2016), 10-18. https://doi.org/10.5606/fng.transplantasyon.2016.003.
JAMA Arat M. Hematopoetik kök hücrelerin klinik kullanımı. İstanbul Bilim Üniversitesi Florence Nightingale Transplantasyon Dergisi. 2016;1:10–18.
MLA Arat, Mutlu. “Hematopoetik kök hücrelerin Klinik kullanımı”. İstanbul Bilim Üniversitesi Florence Nightingale Transplantasyon Dergisi, vol. 1, no. 1, 2016, pp. 10-18, doi:10.5606/fng.transplantasyon.2016.003.
Vancouver Arat M. Hematopoetik kök hücrelerin klinik kullanımı. İstanbul Bilim Üniversitesi Florence Nightingale Transplantasyon Dergisi. 2016;1(1):10-8.
 Download Cover Image